$NORD
Nordicus Partners Corp Stock $nord

$nord Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045927 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024 Q1
Revenue		$2.500K	$2.500K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$86.63K
YoY Change			-96.59%
% of Gross Profit
Research & Development		$343.2K
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$509.9K	$86.63K
YoY Change		426.31%	-96.59%
Operating Profit		-$507.4K
YoY Change		423.73%
Interest Expense			$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net		-$1.00	$0.00
YoY Change		-99.95%	-100.0%
Pretax Income		-$507.4K	-$84.13K
YoY Change		413.61%	-96.69%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$500.8K	-$84.13K
YoY Change		406.92%	-96.69%
Net Earnings / Revenue		-20031.4%	-3365.2%
Basic Earnings Per Share		-$0.10
Diluted Earnings Per Share		-$0.10	-$0.01
COMMON SHARES
Basic Shares Outstanding	17.19M shares	49.46M shares	11.03M shares
Diluted Shares Outstanding		4.960M shares

Balance Sheet

Concept	2024 Q3	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments		$49.93K
YoY Change		598.32%
Cash & Equivalents	$46.13K	$49.93K
Short-Term Investments
Other Short-Term Assets		$0.00
YoY Change		-100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$118.5K	$49.93K
YoY Change	999.79%	-4.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$18.64M
YoY Change
Intangibles	$223.3K	$0.00
YoY Change
Long-Term Investments		$1.750M
YoY Change
Other Assets		$7.640K
YoY Change		191.05%
Total Long-Term Assets	$20.67M	$1.758M
YoY Change	1077.37%	66857.71%
TOTAL ASSETS
Total Short-Term Assets	$118.5K	$49.93K
Total Long-Term Assets	$20.67M	$1.758M
Total Assets	$20.79M	$1.808M
YoY Change	1076.9%	3185.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$5.020K
YoY Change		-62.76%
Accrued Expenses
YoY Change
Deferred Revenue	$7.500K	$7.500K
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$152.9K	$26.41K
YoY Change	495.0%	-3.52%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$152.9K	$26.41K
Total Long-Term Liabilities		$0.00
Total Liabilities	$152.9K	$26.41K
YoY Change	495.0%	-3.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.64M	-$43.88M
YoY Change	5.45%	4.0%
Common Stock	$4.966K	$11.10K
YoY Change	-54.34%	33.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$30.33K	$30.33K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$19.68M	$1.781M
YoY Change
Total Liabilities & Shareholders Equity	$20.79M	$1.808M
YoY Change	1076.9%	3185.0%

Cashflow Statement

Concept	2024 Q3	2024 Q1
OPERATING ACTIVITIES
Net Income	-$500.8K	-$84.13K
YoY Change	406.92%	-96.69%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$107.9K
YoY Change		-52.73%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		114.4K
YoY Change		-50.25%
NET CHANGE
Cash From Operating Activities		-107.9K
Cash From Investing Activities
Cash From Financing Activities		114.4K
Net Change In Cash		6.440K
YoY Change		318.18%
FREE CASH FLOW
Cash From Operating Activities		-$107.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Operating Expenses OperatingExpenses	768064	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-507395	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
	dei	Entity Central Index Key EntityCentralIndexKey	0001011060
CY2024Q1	us-gaap	Assets Current AssetsCurrent	49933	usd
CY2024Q1	NORD	Noncurrent Asset Website NoncurrentAssetWebsite	7640	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2024Q1	us-gaap	Other Assets OtherAssets		usd
CY2024Q1	us-gaap	Goodwill Goodwill		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest		usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q3	NORD	Consulting Expense ConsultingExpense		usd
CY2023Q3	NORD	Consulting Expense ConsultingExpense		usd
	NORD	Consulting Expense ConsultingExpense		usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	NORD	Derecognition Of Deferred Revenue Upon Consolidation Of Orocidin As DerecognitionOfDeferredRevenueUponConsolidationOfOrocidinAs		usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	NORD	Common Stock Issued For Acquisition Of Orocidin As CommonStockIssuedForAcquisitionOfOrocidinAs		usd
	NORD	Forgiveness Of Debt Related Party ForgivenessOfDebtRelatedParty		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-11737
	dei	Entity Registrant Name EntityRegistrantName	NORDICUS PARTNERS CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3186647
	dei	Entity Address Address Line1 EntityAddressAddressLine1	280 South Beverly Dr.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 505
	dei	Entity Address City Or Town EntityAddressCityOrTown	Beverly Hills
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90212
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	666-0750
	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17188166	shares
CY2024Q3	us-gaap	Cash Cash	46131	usd
CY2024Q1	us-gaap	Cash Cash	49933	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	72338	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	118469	usd
CY2024Q3	NORD	Noncurrent Asset Website NoncurrentAssetWebsite	10014	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	223316	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	41424	usd
CY2024Q3	us-gaap	Goodwill Goodwill	18641985	usd
CY2024Q3	us-gaap	Long Term Investments LongTermInvestments	1750000	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	1750000	usd
CY2024Q3	us-gaap	Assets Assets	20785208	usd
CY2024Q1	us-gaap	Assets Assets	1807573	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	145368	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5019	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7500	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7500	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	152868	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	26405	usd
CY2024Q3	us-gaap	Liabilities Liabilities	152868	usd
CY2024Q1	us-gaap	Liabilities Liabilities	26405	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4965626	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4965626	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1110226	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1110226	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	4966	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1110	usd
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	154	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	154	shares
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	30328	usd
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	30328	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64333434	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45696761	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13693	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2848	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44642481	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43883527	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	19679284	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1781168	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	953056	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20632340	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1781168	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20785208	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1807573	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2500	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2500	usd
CY2024Q3	us-gaap	Officers Compensation OfficersCompensation	49104	usd
CY2023Q3	us-gaap	Officers Compensation OfficersCompensation	30593	usd
	us-gaap	Officers Compensation OfficersCompensation	98546	usd
	us-gaap	Officers Compensation OfficersCompensation	57593	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	46428	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	56868	usd
	us-gaap	Professional Fees ProfessionalFees	72210	usd
	us-gaap	Professional Fees ProfessionalFees	76793	usd
	NORD	Consulting Expense ConsultingExpense	150000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	71154	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9420	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	104099	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14084	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343209	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	343209	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	509895	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	96881	usd
	us-gaap	Operating Expenses OperatingExpenses	148470	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-96881	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-765564	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-148470	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1909	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9384	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1909	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9384	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-507396	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98790	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-765565	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-139086	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-507396	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-98790	usd
	us-gaap	Profit Loss ProfitLoss	-765565	usd
	us-gaap	Profit Loss ProfitLoss	-139086	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6611	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6611	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-500785	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-98790	usd
	us-gaap	Net Income Loss NetIncomeLoss	-758954	usd
	us-gaap	Net Income Loss NetIncomeLoss	-139086	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16771	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3104	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16541	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3165	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-484014	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-101894	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-742413	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142251	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4960079	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4960079	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1084665	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1084665	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4050313	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4050313	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	972283	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	972283	shares
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1781168	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	18050000	usd
CY2024Q2	NORD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	60000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	138979	usd
CY2024Q2	NORD	Adjustments To Additional Paid In Forgiveness Of Debt Related Party AdjustmentsToAdditionalPaidInForgivenessOfDebtRelatedParty	13886	usd
CY2024Q2	NORD	Stock Issued During Period Recognition Of Noncontrolling Interest StockIssuedDuringPeriodRecognitionOfNoncontrollingInterest	950000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-258169	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-230	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20735634	usd
CY2024Q3	NORD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	194000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	193330	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-507396	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	16771	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20632340	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27658	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1750000	usd
CY2023Q2	NORD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	25000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-40296	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-61	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1762301	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1762301	usd
CY2023Q3	NORD	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	80000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-98790	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3104	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1740407	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1740407	usd
	us-gaap	Profit Loss ProfitLoss	-765565	usd
	us-gaap	Profit Loss ProfitLoss	-139086	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	138979	usd
	NORD	Derecognition Of Deferred Revenue Upon Consolidation Of Orocidin As DerecognitionOfDeferredRevenueUponConsolidationOfOrocidinAs	-7500	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	42431	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1932	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-44481	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	41424	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	110570	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8528	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7500	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-12127	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-599871	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-100136	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2374	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	134572	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	132198	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1924	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	193330	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	254000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	105000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	447330	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106924	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20343	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6788	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16541	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3165	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49933	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7149	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46131	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10772	usd
	us-gaap	Stock Issued1 StockIssued1	1750000	usd
	NORD	Common Stock Issued For Acquisition Of Orocidin As CommonStockIssuedForAcquisitionOfOrocidinAs	18050000	usd
	NORD	Forgiveness Of Debt Related Party ForgivenessOfDebtRelatedParty	13886	usd
CY2024Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-10 reverse stock split
CY2024Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zRWCwLd6hWtl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_868_zuQIZJQ8UXJ5">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the useful lives of long-lived assets and recoverability of those assets, and impairment in fair value of goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zqnWqF9fKoq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86B_zs1ACoIkT9Z9">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We also maintain cash in foreign bank accounts that are not federally insured. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	30000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	607500	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	653000	shares
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44642481	usd
	NORD	Adjustments To Additional Paid In Forgiveness Of Debt Related Party AdjustmentsToAdditionalPaidInForgivenessOfDebtRelatedParty	13886	usd
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	NORD	Preferred Stock Issued And Redeemed Shares PreferredStockIssuedAndRedeemedShares	500000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares

Files In Submission

Name	View Source	Status
0001493152-24-045927-index-headers.html	Edgar Link	pending
0001493152-24-045927-index.html	Edgar Link	pending
0001493152-24-045927.txt	Edgar Link	pending
0001493152-24-045927-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nord-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nord-20240930_cal.xml	Edgar Link	unprocessable
nord-20240930_def.xml	Edgar Link	unprocessable
nord-20240930_lab.xml	Edgar Link	unprocessable
nord-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NORD
Nordicus Partners Corp Stock $nord

2024 Q4 Form 10-Q Financial Statement

#000149315224045927 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NORD Nordicus Partners Corp Stock $nord

2024 Q4 Form 10-Q Financial Statement

#000149315224045927 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NORD
Nordicus Partners Corp Stock $nord